resmed

Don't sleep on this alternative treatment to CPAP in the massive and growing obstructive sleep apnea market

ResMed's result proves that the best time to buy is when others are "irrationally fearful" - as they have been over the last six months.

How ResMed is steadily becoming a more dominant player in the global OSA duopoly

ResMed CEO Mick Farrel says weight loss drugs could be bringing more patients into the CPAP funnel.

Historically, healthcare has been an all-weather sector, with stocks that can compound earnings over the cycle. The pandemic reversed this trend for the ASX 200...

In February of this year, I laid out three reasons why we at Firetrail Investments believe ResMed (ASX: RMD) was set for future growth in Resting easy with ResMed....

In June this year, Philips was forced to recall 14 sleep and respiratory care devices due to safety concerns. While this has been a setback for the Dutch company, it’s...